Recently, Abbott's first imported high-purity prescription fish oil formulation, Omar( ω- 3 fatty acid ethyl ester 90 soft capsules), has been prescribed in several hospitals across the country, marking the official entry of this high triglyceride treatment drug into clinical application in China and providing a new treatment option for the general population with dyslipidemia.
This year, the 2023 version of the "China Lipid Management Guidelines" (hereinafter referred to as the "Guidelines"), jointly prepared by academic institutions such as the China Lipid Management Guidelines Revision Joint Expert Committee, was officially released. The "Guidelines" propose new blood lipid control goals and strategies. At present, more than 40% of adults in China have issues with abnormal blood lipids, and the number of cardiovascular diseases is as high as 330 million. Despite adopting various methods to actively control blood lipid levels and protect vascular health, it has always been difficult to curb the high incidence of cardiovascular diseases. In recent years, scientists have been actively searching for effective methods to prevent and treat cardiovascular diseases, proposing that the best plan for blood lipid control is to use statins and high-purity eicosapentaenoic acid ethyl ester (IPE) for "combination therapy". The high-purity fish oil EPA soft capsules, which have been launched by Chengyi Pharmaceutical, are rich in ethyl eicosapentaenoate (IPE) and will enter clinical applications in China, providing a "new treatment option" for the general population with dyslipidemia.
For many years, Cheng Yi Pharmaceutical has made unremitting efforts to conquer the key technology of high-purity medicinal fish oil. The fish oil purification and separation technology has reached the international advanced level, and currently can produce EPA and DHA with a purity of ≥ 98%. At the end of 2022, Cheng Yi Pharmaceutical launched two "Sankang" series of fish oil health foods based on its own high-purity EPA fish oil raw materials, namely Sankang/Wasepa brand fish oil soft capsules (EPA ≥ 93%), ω- 3 ≥ 96.6%); Yuzhongyou/Yushengkang Brand Fish Oil Soft Capsules (EPA ≥ 50%, ω- 3 ≥ 75%). In addition, the self produced raw materials are also being used in the research and development application of Yaozhunzi EPA soft capsules. Multiple clinical studies have shown that receiving fish oil products with higher purity results in greater benefits for participants. Taking fish oil products with lower purity not only does not have a good lipid-lowering effect, but also can affect physical health due to excessive intake of oil. Meanwhile, EPA and DHA each have different effects, which means that the efficacy of fish oil formulations is reflected in purity and composition, while Cheng Yi Pharmaceutical has taken the lead in the development of high-purity fish oil products.
At present, the cornerstone drugs for lowering blood lipids in the world are statins, which have certain limitations in their lipid-lowering intensity and patient tolerance. Even high-intensity statins, such as 20mg rosuvastatin and 40mg atorvastatin, can reduce blood lipids by only about 50%. The Guide suggests that the use of moderate intensity statins to control blood lipids is the preferred strategy for Chinese people to take lipid lowering drugs, and the effect of moderate intensity statins on reducing blood lipids can only reach 25%~50%. Therefore, for some patients with high or extremely high baseline levels of blood lipids, it is difficult to control blood lipids within a reasonable range by using statins alone. In this case, combined medication is needed to strengthen blood lipid control.
After repeated experiments, scientists have found that statins and high-purity ethyl eicosapentaenoate (IPE) are one of the better combination drugs. Among them, high-purity IPE has the effect of reducing triglycerides, and there is clear clinical evidence of cardiovascular protection. It is the preferred combination of statins to strengthen triglyceride control. The American diabetes Association (ADA), AHA, ESC, the National Lipid Association (NLA), the Food and Drug Administration (FDA) and other authoritative organizations all recommend that high purity fish oil products can be added to ASCVD and high-risk patients of ASCVD who still have high triglyceride levels (<500mg/dL) after the use of statins to further reduce cardiovascular risk. (Ling Fei)